TIL manufacture requires the fragmentation or enzymatic digestion of excised patient-derived tumours, the enrichment of tumour-reactive TILs through IFN-γ-based selection following stimulation with autologous tumours, and a rapid expansion protocol (REP) in the presence of IL-2 and anti-CD3 antibodies to achieve target cell doses for patient treatment [17,19]. The gene discussed is IFNG; the disease is neoplasm.